Noticias de AGEN_US

Noticias del mercado

Últimas noticias sobre AGEN_US — 216 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: AGEN_US ✕ 216 resultados
09/04/2026 AGEN_US — MSN
Agenus (AGEN) price target increased by 25.68% to 15.81
06/04/2026 AGEN_US — Stock Titan
Armen of Agenus (NASDAQ: AGEN) takes salary in stock
03/04/2026 AGEN_US — The National Law Review
Agenus Announces Data from Phase II Study of BOT+BAL in Combinati
03/04/2026 AGEN_US — Yahoo Finance
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
03/04/2026 AGEN_US — Yahoo Finance
Can Agenus (AGEN) Run Higher on Rising Earnings Estimates?
03/04/2026 AGEN_US — Yahoo Finance
All You Need to Know About Agenus (AGEN) Rating Upgrade to Strong Buy
03/04/2026 AGEN_US — news.google.com
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
03/04/2026 AGEN_US — BioPharma APAC
Agenus Inc. Initiates Landmark Phase 3 BATTMAN Trial In MSS Metastatic Colorectal Cancer
03/04/2026 AGEN_US — MarketBeat
HC Wainwright Analysts Boost Earnings Estimates for Agenus
03/04/2026 AGEN_US — Yahoo Finance
Has Agenus (AGEN) Outpaced Other Medical Stocks This Year?
03/04/2026 AGEN_US — Yahoo Finance
Why Agenus (AGEN) is a Top Momentum Stock for the Long-Term
03/04/2026 AGEN_US — Business Wire
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
03/04/2026 AGEN_US — BioSpace
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
03/04/2026 AGEN_US — Oncodaily
Phase 3 BATTMAN Trial Launches BOT/BAL in MSS or pMMR Metastatic Colorectal Cancer
03/04/2026 AGEN_US — Bitget ES ← EN
¿Agenus (AGEN) ha superado a otras acciones de atención médica en lo que va de año?
02/04/2026 AGEN_US — BioPharma APAC
Agenus Inc. Initiates Landmark Phase 3 BATTMAN Trial In MSS Metastatic Colorectal Cancer
02/04/2026 AGEN_US — BioPharma APAC
Agenus Inc. Initiates Landmark Phase 3 BATTMAN Trial In MSS Metastatic Colorectal Cancer
02/04/2026 AGEN_US — BioSpace
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
02/04/2026 AGEN_US — Stock Titan
Agenus (NASDAQ: AGEN) director awarded 2,448 Deferred Stock Units as board pay
01/04/2026 AGEN_US — MarketScreener ES ← EN
Agenus Inc anuncia el primer paciente inscrito en el ensayo mundial de fase 3 BATTMAN de combinación de inmunoterapia BOT más BAL en cáncer colorrectal metastásico MSS o PMMR

Página 9 de 11

keyboard_arrow_up